Skip To Main Content
Edvan Q. Crusoé on Muck Rack

Edvan Q. Crusoé

As seen in: Wiley Online Library
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Edvan Q.

Contact Edvan Q., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Real-world outcomes of daratumumab, bortezomib, thalidomide and dexamethasone (Dara-VTd) induction and lenalidomide maintenance in transplant-eligible multiple myeloma

|
By Jayr Schmidt Filho, Edvan Q. Crusoé, Glaciano Ribeiro
| Wiley Online Library Verified
To the Editor, Maintenance lenalidomide after autologous haematopoietic stem cell transplantation (AHSCT) is standard for transplant-eligible newly diagnosed multiple myeloma (TENDMM), based on trials demonstrating an overall survival (OS) benefit following doublet- and triplet-based induction with proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs).1, 2 Recently, incorporating anti-cluster of differentiation 38 (CD38) monoclonal antibodies into first-line induction with an IMiD...
Open in Who Shared Issue with article?
See all 1 articles